前列腺癌70Gy至80Gy调强放疗:六年结局与晚期毒性预测因素
该研究纳入277例接受70Gy、74Gy或80Gy调强放疗的前列腺癌患者,中位随访77个月,5年≥2级晚期直肠和泌尿毒性累计发生率分别为6.3%和25.3%,80Gy增加直肠毒性风险,基线IPSS≥8和膀胱D2%≥73Gy预测泌尿毒性,5年生化无进展生存率为81.0%。
要点
- 80Gy较70/74Gy增加晚期直肠≥2级毒性风险(HR=2.96)。
- 74Gy组基线IPSS≥8和膀胱D2%≥73Gy预测晚期泌尿毒性。
- 5年生化无进展生存率低危97.5%、中危84.9%、高危66.4%。
核心结论
- 晚期直肠毒性随剂量升高而增加,80Gy较70/74Gy增加直肠毒性风险(HR=2.96)。
- 晚期泌尿毒性预测因素包括膀胱Dmax≥74Gy、膀胱D2%≥73Gy和基线IPSS≥8。
研究设计与样本
- 回顾性分析277例接受调强放疗(IMRT)的前列腺癌患者,剂量为70Gy(10.8%)、74Gy(63.9%)和80Gy(25.3%),未行盆腔照射。
- 46.1%患者接受短程或长程雄激素剥夺治疗(ADT),毒性采用CTCAE v4.0评估,中位随访77个月(范围15-150个月)。
主要发现
- 5年≥2级晚期直肠和泌尿毒性累计发生率分别为6.3%(95%CI=3.8%-10.3%)和25.3%(95%CI=19.8%-31.8%)。
- 多因素分析中,仅剂量(80Gy vs 74和70Gy)增加直肠毒性风险(HR=2.96 [1.07; 8.20])。
- 74Gy组中,基线IPSS≥8(HR=2.40 [1.08; 5.35])和膀胱D2%≥73Gy(HR=3.29 [1.36; 7.98])预测膀胱毒性。
- 5年生化无进展生存率全组81.0% [74.5%; 86.0%],低危97.5% [83.5%; 99.6%],中危84.9% [76.7%; 90.3%],高危66.4% [51.8%; 77.4%]。
- D'Amico低危(HR=0.09 [0.01; 0.69])和中危(HR=0.50 [0.28; 0.88])以及PSA nadir≥0.2 ng/ml(HR=1.79 [1.01; 3.21])预测生化复发。
关键数值与推荐
- 5年≥2级晚期直肠毒性累计发生率6.3%(95%CI=3.8%-10.3%),泌尿毒性25.3%(95%CI=19.8%-31.8%)。
- 80Gy vs 74和70Gy的直肠毒性HR=2.96 [1.07; 8.20]。
- 74Gy组膀胱毒性预测:基线IPSS≥8的HR=2.40 [1.08; 5.35],膀胱D2%≥73Gy的HR=3.29 [1.36; 7.98]。
- 5年生化无进展生存率:全组81.0% [74.5%; 86.0%],低危97.5% [83.5%; 99.6%],中危84.9% [76.7%; 90.3%],高危66.4% [51.8%; 77.4%]。
临床怎么用
- 前列腺癌IMRT选择80Gy时需权衡晚期直肠毒性风险增加。
- 对接受74Gy的患者,应关注基线IPSS≥8和膀胱D2%≥73Gy以预测泌尿毒性。
- 生化复发风险分层可参考D'Amico风险组和PSA nadir≥0.2 ng/ml。
局限性
- 原文未报告研究类型为回顾性还是前瞻性。
- 原文未报告毒性预测模型的验证情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report grade ≥2 overall late rectal and urinary toxicities in patients (pts) with prostate cancer treated by intensity-modulated radiotherapy (IMRT) at 3 dose-levels. Identify predictors of radiation toxicity and report biochemical progression free survival (bPFS). METHODS: A total of 277 pts were treated with 70Gy (10.8%), 74Gy (63.9%) and 80 Gy (25.3%) using IMRT without pelvic irradiation were analyzed. Short or long-course androgen deprivation therapy (ADT) was allowed in 46.1% of pts. The toxicity was described using the Common Terminology Criteria for Adverse Events (CTCAE) v4.0 scale. Cox regression models addressed demographics, disease and dosimetry characteristics as potential predictors of late grade ≥2 toxicity after adjusting for other modifying factors. RESULTS: The median follow-up was 77 months (range 15; 150). There was no grade ≥4 toxicity. The 5-year cumulative rate of grade ≥2 late rectal and urinary toxicities was 6.3% (95% CI = 3.8%; 10.3%) and 25.3% (95% CI = 19.8%; 31.8%) respectively. In multivariate analysis, only the dose (80Gy vs 74 and 70Gy) was found to increase the risk of rectal toxicity (HR = 2.96 [1.07; 8.20]). For pts receiving 74 Gy, International Prostate Symptom Score (IPSS) at baseline ≥8 (HR = 2.40 [1.08; 5.35]) and dose ≥73Gy delivered in more than 2% of bladder (D2%) were found to be predictors of bladder toxicity (HR = 3.29 [1.36; 7.98]). The 5-year biochemical relapse free survival was 81.0% [74.5%; 86.0%] in the entire population, 97.5% [83.5%; 99.6%] in the low risk group, 84.9% [76.7%; 90.3%] in the intermediate risk group and 66.4% [51.8%; 77.4%] in the high-risk group. D'Amico low (HR = 0.09 [0.01; 0.69]) and intermediate risk groups (HR = 0.50 [0.28; 0.88]) as well as PSA nadir ≥0.2 ng/ml (HR = 1.79 [1.01; 3.21]) were predictive of biochemical relapse. CONCLUSIONS: The rate of late rectal toxicity increased with higher doses, while Dmax ≥74Gy, D2% ≥ 73Gy for bladder wall and baseline IPSS ≥8 increased late urinary toxicity.
引用
- Jolnerovski M, Salleron J, Beckendorf V, et al. Intensity-modulated radiation therapy from 70Gy to 80Gy in prostate cancer: six- year outcomes and predictors of late toxicity. Radiat Oncol. 2017. PMID: 28622770. doi:10.1186/s13014-017-0839-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。